Growth Investing Risks

Showing 3516 articles
Business

Gilead Sciences Bets on Precision Oncology to Power Next Growth Phase

Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.

Business

Palantir Shatters Records as U.S. AI Demand Fuels Historic Growth

Palantir Technologies' fourth-quarter earnings reveal a seismic shift, with U.S. commercial revenue for its AI Platform soaring 137%. The data analytics firm posted its highest growth rate as a public company, powered by massive government contracts and enterprise adoption, while setting aggressive targets for the year ahead.

Business

IDEXX Laboratories Posts Strong Q4 Growth, Unveils Ambitious 2026 Outlook on Diagnostic Innovation

IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.